BR1400-B

Boryung Pharmaceutical Co., Ltd · Phase 2 active Small molecule

BR1400-B is an investigational therapeutic in phase 2 development by Boryung Pharmaceutical with an undisclosed or proprietary mechanism of action.

At a glance

Generic name	BR1400-B
Also known as	Placebo
Sponsor	Boryung Pharmaceutical Co., Ltd
Modality	Small molecule
Phase	Phase 2

Mechanism of action

Limited public information is available regarding the specific molecular mechanism of BR1400-B. As a phase 2 candidate from Boryung Pharmaceutical, the drug is still in clinical development with mechanism details potentially proprietary or not yet fully disclosed in accessible literature.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BR1400-B CI brief — competitive landscape report
BR1400-B updates RSS · CI watch RSS
Boryung Pharmaceutical Co., Ltd portfolio CI